Skip to main content
OpenTrials
Completed

NCT Number: NCT02169154

A Safety Study to Investigate the Skin Irritancy Potential of Diclofenac-Menthol Gel

This research study is being conducted to investigate the skin irritancy potential of a new medication which contains two active ingredients (diclofenac and menthol) together in a gel formulation and is being developed to treat mild to moderate pain and inflammation, such as acute sport injuries, sprains and strains.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

TKL Research Inc

Paramus, New Jersey, 07652, United States

About this study

Approximately 36 healthy subject volunteers will be exposed to seven test products (study treatment gel and six control products) simultaneously for 21 consecutive days. The seven test products will be applied using a 7-channel patch assembly that will be affixed to the infrascapular areas of the back of each subject for approximately 24 hours daily.

The subject will return to the clinic to undergo a skin irritation assessment at approximately 24 hours after the time the patch assembly was initially affixed.

During the visits, doctors or trained staff members will examine the signs of irritation (if any) of the skin where the test products are applied. The skin irritation assessment will primarily characterize the test products individually in terms of symptomatology using a 7-point categorical scale ranging from 1 (glazing and/or wrinkling) to 7 (erosion and/or vesiculation).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male/female volunteer ≥18 years
  • No systemic/dermatologic disorder

Exclusion criteria

  • Visible skin disease at the site of application that might interfere with skin assessments
  • Allergy or hypersensitivity to NSAIDs or menthol or any of the excipients in the test product
  • History of physical or psychiatric illness, or medical disorder
  • Recent history of alcohol or drug abuse
  • Pregnant or lactating females

Treatment and study plan

1% Diclofenac Sodium

Drug

1% diclofenac sodium

3% menthol

Drug

3% Menthol

0.09% Menthol

Drug

0.09% Menthol

0.2% Sodium Lauryl Sulfate

Drug

0.2% Sodium Lauryl Sulfate

0.9% saline

Drug

0.9% Saline

Primary outcomes

  1. Treatment mean cumulative irritation score

    Time frame: Day 21

    Cumulative irritation scores will be defined daily as the sum of irritation score and grade number

  2. Adverse event assessment

    Time frame: 21 days + 5 days follow-up

    Adverse events will be graded on a three-point scale: 1. Mild-easily tolerated, causing minimal discomfort and not interfering with normal everyday activities; 2. Moderate-sufficiently discomforting to interfere with normal everyday activities; 3. Severe-any event that prevents normal everyday activities

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

A Cumulative Skin Irritation Study Investigating the Skin Irritancy Potential of MFC51123 Diclofenac-Menthol Gel

Important dates

Study start
2014
Primary completion
2014
Study completion
2014
First posted
Jun 23, 2014
Registry last updated
Jun 29, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.